Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.

Abstract: A coated glass pharmaceutical package includes a glass body having a Type 1 chemical durability according to USP 660, at least a class A2 base resistance or better according to ISO 695, and at least a type HGB2 hydrolytic resistance or better according to ISO 719, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A lubricous coating having a thickness of less than or equal to 90 nm may be positioned on at least a portion of the exterior surface of the glass body but not on any portion of the interior surface. The portion of the coated glass package with the lubricous coating comprises a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle including exposure to a temperature of 250° C. for a time period of 30 minutes.

Abstract: Host data can be received at a memory sub-system. A determination can be made that the host data exceeds a threshold size associated with an encryption operation. The host data can be separated into segments based on the threshold size associated with the encryption operation. Each of the segments can be encrypted based on the encryption operation. Furthermore, the encrypted segments can be stored at the memory sub-system.

Abstract: The present invention relates to yeast cell wall 5 compositions enriched with mannose, mannose extracts and processes for making the same.

Abstract: Host data can be received at a memory sub-system. A determination can be made that the host data exceeds a threshold size associated with an encryption operation. The host data can be separated into segments based on the threshold size associated with the encryption operation. Each of the segments can be encrypted based on the encryption operation. Furthermore, the encrypted segments can be stored at the memory sub-system.

Abstract: A drone cleaning apparatus includes a drone; and a pressure washer or power washer comprising a wand with nozzle, hose, and motor unit. The wand is fastened to an underside of the drone, with the hose attached to and connecting the wand and the motor unit. When the motor unit is turned on, a liquid jet emanates from the nozzle of the wand and may be directed onto a building for cleaning of the building. A method of making the drone cleaning apparatus, comprises: providing a drone and a pressure washer or power washer comprising a wand with nozzle, hose, and motor unit; attaching the wand to a bottom of the drone; and connecting the hose to the wand and to the motor unit.

Abstract: The present invention relates to yeast cell wall 5 compositions enriched with mannose, mannose extracts and processes for making the same.

Abstract: Modified and/or derivativized ?-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized ?-glucans are demonstrated.

Abstract: The invention relates to a method of fabricating a microneedle array in a substrate, a drug delivery device comprising one or more microneedles extending upwards from the front surface of the substrate, the microneedles having a generally conical-shaped body defined by a plurality of surfaces sloping upwards from a relatively broad base to a tip, and one or more substances coating the microneedles, the one or more substances being operable to be administered to a patient, wherein the tips of the one or more microneedles are sufficiently sharp to penetrate an outer layer of the skin of the patient, and a method of administering one or more substances to a patient using the device.

Abstract: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Abstract: A resonant switching power system operates with two resonant frequencies. A first frequency depends on the secondary leakage inductance of an output transformer and capacitor. The first frequency varies with changes in the load because load changes alter the leakage inductance. A second resonant frequency depends on the gate source capacitance of two MOSFET power devices in the circuit and the leakage inductance of the circuit's driving transformer. Power is thereby supplied that is always in phase with the load so that switching in the power supply occurs when current is near zero. High thermal efficiency is thereby achieved.

Abstract: Aryl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Abstract: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Abstract: The invention relates to a method of fabricating a microneedle array in a substrate, a drug delivery device comprising one or more microneedles extending upwards from the front surface of the substrate, the microneedles having a generally conical-shaped body defined by a plurality of surfaces sloping upwards from a relatively broad base to a tip, and one or more substances coating the microneedles, the one or more substances being operable to be administered to a patient, wherein the tips of the one or more microneedles are sufficiently sharp to penetrate an outer layer of the skin of the patient, and a method of administering one or more substances to a patient using the device.